Alexion Registration – PNH Essentials 2025-2026

Join healthcare professionals from around Australia for the inaugural PNH Essentials Educational Program as we explore the latest perspectives and insights from leading experts on the management of paroxysmal nocturnal haemoglobinuria (PNH) in today’s clinical setting, with a focus on C5 inhibitors and dual inhibition therapy.*

  • Video mini-series: episodes released from October 2025 to March 2026
  • Live online panel discussion event and real-time audience Q&A: 26 March 2026, 7.00-8.00pm AEDT (please check local time for your time zone)

*For information about other PNH treatments, please refer to their respective Product Information.

 

Complete the form below to register for the PNH Essentials Educational Program

Registered participants receive:

  • Direct access to each video episode – no login required
  • Timely updates including details of video release and program activities
  • Opportunities to participate in interactive polling and share your perspective
  • Streamlined registration for the live online panel discussion event (tick the box to request, we do the rest)
  • Early-bird access to submit your questions to be answered during the live panel discussion event.

"*" indicates required fields

Program participation

Please help Alexion gauge the perceived value of the different components of this educational program event by completing this part of the survey.# All data will be de-identified before analysis.
The PNH Essentials program includes progressive release of five brief episodes in the video mini-series (maximum duration of 10-15 minutes per video), accompanied by an email series including participant polling and key points summaries, followed by a live online panel discussion event with real-time audience Q&A (online). Please indicate your level of interest in each component of the PNH Essentials program. (1=Limited interest, 5=Strong interest)
1 = Limited interest2345 = Strong interest
Video 1: The role for C5 inhibitor therapy as front-line treatment for PNH and the emerging role for dual inhibition therapy in the second-line setting*
Video 2: Importance of controlling intravascular haemolysis and severity of thrombosis in PNH
Video 3: Understanding breakthrough haemolysis, the evidence for different treatments and management strategies in PNH*
Video 4: Dual inhibition therapy for management of extravascular haemolysis in PNH*
Video 5: Safety considerations in PNH management with C5 inhibitors and dual inhibition therapy*
Live online panel discussion and real-time audience Q&A (live only - recording not available for on-demand viewing after event)
*For information about other PNH treatments, please refer to their respective Product Information.
Tick 'Yes' if you'd like to use your submitted information to be automatically registered for the PNH Essentials live online panel discussion event on 26 March 2026.*
Once registration is open, you will be added to the online event registration list, and will be sent a registration confirmation email with your access details. You will also receive reminder emails closer to the event date.

Pre-Program Questions

Please help Alexion gauge the educational value of this program by completing this survey. The results will be compared to a similar survey completed at the end of the program. All data will be de-identified before analysis. Note this is not an assessment; there are no right or wrong answers.
1. How many PNH cases have you managed or been involved with in the past year?*
(1=Not at all confident, 5=Extremely confident)
(1=Not at all confident, 5=Extremely confident)
(1=Not at all confident, 5=Extremely confident)
(1=Not at all confident, 5=Extremely confident)
(1=Not at all familiar, 5=Extremely familiar)

Access Alexion Assist

The PNH Essentials video mini-series will be hosted on Alexion Assist. Videos will be released progressively from October 2025 to March 2026.
Tick 'Yes' if you'd like to use your submitted information to simultaneously register for Alexion Assist, a private HCP portal where videos, meeting presentations, case studies, and other PNH resources can be accessed on-demand. Following the event, you will receive an email with your login details and a temporary password.*

Consent to Receive Electronic Messaging

By submitting this registration form, you consent to receiving electronic messages from Alexion regarding the program for which you are registering and messages from Alexion about rare diseases, approved products and services of Alexion, other scientific information, invitations to events and market research. You have a right to withdraw your consent at any time in the future. A condition of access is that participants disclose if they are employees of a Pharmaceutical company. Alexion reserves the right to decline access to participants who are not involved in the management of patients who are on Alexion therapies. Alexion recognises the importance of protecting the privacy of personal information it collects and respects your rights to privacy under the Privacy Act 1988 (Cth). If you require further information about how Alexion collects, uses, shares and protects information, please see the full privacy notice. If you would like to withdraw your consent for inclusion on Alexion mailings, or would like to access your personal information, please email privacyofficer.austraIia@alexion.com.

This program is intended for healthcare professionals only and should not be disseminated to others.
© 2025. All rights reserved. Alexion Pharmaceuticals Australasia Pty Ltd. ACN 132 343 036. Macquarie Park, NSW 2113. October 2025. AU/UNB-P/0024.